Literature DB >> 1514644

L-arginine restores endothelium-dependent relaxation in pulmonary circulation of chronically hypoxic rats.

S Eddahibi1, S Adnot, C Carville, Y Blouquit, B Raffestin.   

Abstract

We investigated whether loss of endothelial-derived relaxing factor (EDRF) activity in the pulmonary vessels of chronically hypoxic rats could be restored by pretreatment with L-arginine. We measured vasodilation to acetylcholine (ACh), calcium ionophore A23187, or linsidomine (Sin-1) under conditions of increased vascular tone induced by U-46619 (50 pmol/min), as well as vasoconstriction to endothelin-1 (ET) in isolated lungs pretreated with meclofenamate (3 microM). In lungs from normoxic (N) rats, in vitro L- or D-arginine (10(-3) M) did not alter vasodilation to the endothelium-dependent agents ACh (10(-9)-10(-6) M) and A23187 (10(-9)-10(-7) M), but NG-monomethyl-L-arginine (10(-3) M) completely abolished it. In lungs from rats exposed to 3 wk of hypoxia (H), vasodilation to ACh or A23187 was fully restored after in vitro L-arginine (10(-3) M) or N alpha-benzoyl-L-arginine (5 x 10(-5) M) but remained abolished after D-arginine, L-citrulline, L-ornithine, or L-argininosuccinic acid. In vivo pretreatment of H rats with L-arginine (300 mg/kg iv) 30 min before isolating the lung also restored vasodilation to A23187. Vasodilation to the endothelium-independent agent Sin-1 was similar in both groups of lungs and was not altered by in vitro L-arginine. L-arginine attenuated the increased pressor response to ET (300 pmol) of H rat lungs but had no effect in N rats. Our results demonstrate that loss of EDRF activity associated with hypoxic pulmonary hypertension may be reversed by supplying L-arginine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1514644     DOI: 10.1152/ajplung.1992.263.2.L194

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Essential role of L-arginine uptake and protein tyrosine kinase activity for NO-dependent vasorelaxation induced by stretch, isometric tension and cyclic AMP in rat pulmonary arteries.

Authors:  D Hucks; N M Khan; J P Ward
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Involvement of accumulated endogenous NOS inhibitors and decreased NOS activity in the impaired neurogenic relaxation of the rabbit proximal urethra with ischaemia.

Authors:  H Masuda; T Tsujii; T Okuno; K Kihara; M Goto; H Azuma
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

3.  Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats.

Authors:  C Kouyoumdjian; S Adnot; M Levame; S Eddahibi; H Bousbaa; B Raffestin
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

4.  Critical dependence of the NO-mediated component of cyclic AMP-induced vasorelaxation on extracellular L-arginine in pulmonary arteries of the rat.

Authors:  D Hucks; J P Ward
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

5.  Changes in functional and histological distributions of nitric oxide synthase caused by chronic hypoxia in rat small pulmonary arteries.

Authors:  Mikiyasu Shirai; James T Pearson; Akito Shimouchi; Noritoshi Nagaya; Hirotsugu Tsuchimochi; Ishio Ninomiya; Hidezo Mori
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

6.  Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide.

Authors:  R M Tuder; B E Flook; N F Voelkel
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 7.  Regulation of endothelial nitric oxide synthase activity by protein-protein interaction.

Authors:  Yunchao Su
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

8.  Combined oral administration of L-arginine and tetrahydrobiopterin in a rat model of pulmonary arterial hypertension.

Authors:  C Schreiber; M S Eilenberg; A Panzenboeck; M P Winter; H Bergmeister; R Herzog; J Mascherbauer; I M Lang; D Bonderman
Journal:  Pulm Circ       Date:  2017-04-04       Impact factor: 3.017

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.